President Donald Trump has introduced a new website designed to provide patients with access to discounted prices on certain high-cost prescription drugs in the U.S.
As the current administration rolls out TrumpRx.gov and highlights new efforts to reduce prescription drug costs, federal healthcare policy continues to evolve rapidly for both industry and government stakeholders. To explore what these developments could mean for agencies, contractors and the broader health ecosystem, the Potomac Officers Club will host the rescheduled 2025 Healthcare Summit on Feb. 12. Register today and hear directly from leading voices shaping the future of healthcare.
What Is TrumpRx.gov?
TrumpRx.gov is a federal website designed to help patients access discounted prescription drug prices by offering prices aligned with the lowest amounts paid in other developed countries under a framework known as most-favored-nation, or MFN, pricing, according to a White House fact sheet published Thursday.
The rollout features discounted medicines from five drugmakers—AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer—that were the first to reach MFN pricing deals with the Trump administration.
According to the administration, the site is designed to offer a streamlined user experience and enable patients with valid prescriptions to obtain savings through printable or downloadable coupons or through purchasing channels established by drug manufacturers and integrated into the platform.
The website will feature discounted prices on a range of branded medications and expand over time as more manufacturers reach MFN pricing agreements.
In January, the Department of Health and Human Services issued new guidance clarifying how pharmaceutical firms can offer lower-cost prescription drugs directly to patients.
What Is the MFN Pricing Model?
The administration said the TrumpRx.gov initiative is based on the MFN pricing model, which seeks to align U.S. drug prices with the lowest prices paid by other developed countries. The MFN pricing policy was established through an executive order signed in May 2025.
In late 2025, the White House signed MFN pricing deals with Pfizer and AstraZeneca.
Which Drugs Will See Price Cuts Under TrumpRx.gov?
The administration said patients using TrumpRx.gov will be able to see discounted pricing for 40 high-cost branded prescription drugs.
Ozempic and injectable Wegovy are expected to drop from $1,028 and $1,349 per month to an average of $350, with some dosage levels priced as low as $199. The administration also said the oral version of Wegovy could be available for as little as $149 per month, depending on dosage strength.
Zepbound is also included in the launch lineup, with monthly pricing projected to decline from $1,088 to an average of $346, with some dosages offered as low as $299.
TrumpRx.gov will also offer discounts on fertility medications, which are often purchased out of pocket. Patients could save more than $2,000 per treatment cycle on average. Under the program, Gonal-F may be priced as low as $168 per pen, while Cetrotide is expected to drop from $316 to $22.50 and Ovidrel from $251 to $84.
The fact sheet also cited discounted pricing for other medicines, including Bevespi Aerosphere, Airsupra, Eucrisa, Insulin Lispro and Duavee.
